Options for the future regulation of 'low risk' products
The Therapeutic Goods Administration (TGA) sought comment on proposed options for future regulation of 'low risk products', noting that decisions on significant changes to the regulatory framework would be made by government. Seeking specific feedback on the potential regulatory options for low risk products that were discussed in the consultation document, including which (if any) might be most appropriate and why. The options presented in the paper represent a range of possible regulatory directions for the identified 'low risk' products.
>> Read NICM's submission (PDF, 467.96 KB) (opens in a new window)